Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients

Claudia Fabiani, Antonio Vitale, Donato Rigante, Giacomo Emmi, Alice Bitossi, Giuseppe Lopalco, Jurgen Sota, Silvana Guerriero, Ida Orlando, Stefano Gentileschi, Florenzo Iannone, Bruno Frediani, Mauro Galeazzi, Lorenzo Vannozzi, Gian Marco Tosi, Luca Cantarini

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

To compare the efficacy of adalimumab (ADA) and infliximab (IFX) in patients with non-infectious intermediate uveitis, posterior uveitis, and panuveitis. Demographic, clinical, instrumental, and therapeutic data from patients enrolled were collected at the start of treatment, at 12-month follow-up, and at the last follow-up assessment. One hundred seven patients (46 females, 187 eyes) were enrolled, 66 (61.7%) treated with ADA and 41 (38.3%) with IFX. Bilateral involvement was observed in 80 cases. The mean follow-up was 26.45 ± 21.71 months for ADA patients and 56.60 ± 56.04 months for IFX patients. The overall decrease of uveitis frequency during the first 12 months of treatment was 66.7% in the IFX group and 84.2% in the ADA group, compared to the previous 12 months (p = 0.09). A significantly higher corticosteroid dosage was found among patients treated with ADA at the last follow-up visit (p = 0.008). The percentage of patients co-administered with corticosteroids was significantly higher among ADA patients both at the 12-month visit (p = 0.03) and at the last visit (p = 0.0004). The frequency of uveitic macular edema (UME) was significantly higher among patients treated with ADA compared to those treated with IFX at the 12-month assessment (p = 0.015) and at the last follow-up visit (p = 0.011); central macular thickness was significantly higher in ADA group compared to the IFX group at the last follow-up assessment (p = 0.04). ADA and IFX have shown a similar efficacy in controlling uveitis relapses, but IFX showed a more pronounced corticosteroid sparing effect and a significantly higher capacity in resolving UME compared to ADA.

Original languageEnglish
JournalClinical Rheumatology
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Intermediate Uveitis
Panuveitis
Posterior Uveitis
Observational Studies
Retrospective Studies
Therapeutics
Adrenal Cortex Hormones
Macular Edema
Uveitis
Infliximab
Adalimumab

Keywords

  • Behçet’s disease
  • Macular edema
  • Retinal vasculitis
  • TNF-blocking antibodies
  • Uveitis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis : a retrospective observational study of 107 patients. / Fabiani, Claudia; Vitale, Antonio; Rigante, Donato; Emmi, Giacomo; Bitossi, Alice; Lopalco, Giuseppe; Sota, Jurgen; Guerriero, Silvana; Orlando, Ida; Gentileschi, Stefano; Iannone, Florenzo; Frediani, Bruno; Galeazzi, Mauro; Vannozzi, Lorenzo; Tosi, Gian Marco; Cantarini, Luca.

In: Clinical Rheumatology, 01.01.2018.

Research output: Contribution to journalArticle

Fabiani, C, Vitale, A, Rigante, D, Emmi, G, Bitossi, A, Lopalco, G, Sota, J, Guerriero, S, Orlando, I, Gentileschi, S, Iannone, F, Frediani, B, Galeazzi, M, Vannozzi, L, Tosi, GM & Cantarini, L 2018, 'Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients', Clinical Rheumatology. https://doi.org/10.1007/s10067-018-4228-6
Fabiani, Claudia ; Vitale, Antonio ; Rigante, Donato ; Emmi, Giacomo ; Bitossi, Alice ; Lopalco, Giuseppe ; Sota, Jurgen ; Guerriero, Silvana ; Orlando, Ida ; Gentileschi, Stefano ; Iannone, Florenzo ; Frediani, Bruno ; Galeazzi, Mauro ; Vannozzi, Lorenzo ; Tosi, Gian Marco ; Cantarini, Luca. / Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis : a retrospective observational study of 107 patients. In: Clinical Rheumatology. 2018.
@article{af1c23da4d944b339fe18f5b6c975f4b,
title = "Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients",
abstract = "To compare the efficacy of adalimumab (ADA) and infliximab (IFX) in patients with non-infectious intermediate uveitis, posterior uveitis, and panuveitis. Demographic, clinical, instrumental, and therapeutic data from patients enrolled were collected at the start of treatment, at 12-month follow-up, and at the last follow-up assessment. One hundred seven patients (46 females, 187 eyes) were enrolled, 66 (61.7{\%}) treated with ADA and 41 (38.3{\%}) with IFX. Bilateral involvement was observed in 80 cases. The mean follow-up was 26.45 ± 21.71 months for ADA patients and 56.60 ± 56.04 months for IFX patients. The overall decrease of uveitis frequency during the first 12 months of treatment was 66.7{\%} in the IFX group and 84.2{\%} in the ADA group, compared to the previous 12 months (p = 0.09). A significantly higher corticosteroid dosage was found among patients treated with ADA at the last follow-up visit (p = 0.008). The percentage of patients co-administered with corticosteroids was significantly higher among ADA patients both at the 12-month visit (p = 0.03) and at the last visit (p = 0.0004). The frequency of uveitic macular edema (UME) was significantly higher among patients treated with ADA compared to those treated with IFX at the 12-month assessment (p = 0.015) and at the last follow-up visit (p = 0.011); central macular thickness was significantly higher in ADA group compared to the IFX group at the last follow-up assessment (p = 0.04). ADA and IFX have shown a similar efficacy in controlling uveitis relapses, but IFX showed a more pronounced corticosteroid sparing effect and a significantly higher capacity in resolving UME compared to ADA.",
keywords = "Beh{\cc}et’s disease, Macular edema, Retinal vasculitis, TNF-blocking antibodies, Uveitis",
author = "Claudia Fabiani and Antonio Vitale and Donato Rigante and Giacomo Emmi and Alice Bitossi and Giuseppe Lopalco and Jurgen Sota and Silvana Guerriero and Ida Orlando and Stefano Gentileschi and Florenzo Iannone and Bruno Frediani and Mauro Galeazzi and Lorenzo Vannozzi and Tosi, {Gian Marco} and Luca Cantarini",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s10067-018-4228-6",
language = "English",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer London",

}

TY - JOUR

T1 - Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis

T2 - a retrospective observational study of 107 patients

AU - Fabiani, Claudia

AU - Vitale, Antonio

AU - Rigante, Donato

AU - Emmi, Giacomo

AU - Bitossi, Alice

AU - Lopalco, Giuseppe

AU - Sota, Jurgen

AU - Guerriero, Silvana

AU - Orlando, Ida

AU - Gentileschi, Stefano

AU - Iannone, Florenzo

AU - Frediani, Bruno

AU - Galeazzi, Mauro

AU - Vannozzi, Lorenzo

AU - Tosi, Gian Marco

AU - Cantarini, Luca

PY - 2018/1/1

Y1 - 2018/1/1

N2 - To compare the efficacy of adalimumab (ADA) and infliximab (IFX) in patients with non-infectious intermediate uveitis, posterior uveitis, and panuveitis. Demographic, clinical, instrumental, and therapeutic data from patients enrolled were collected at the start of treatment, at 12-month follow-up, and at the last follow-up assessment. One hundred seven patients (46 females, 187 eyes) were enrolled, 66 (61.7%) treated with ADA and 41 (38.3%) with IFX. Bilateral involvement was observed in 80 cases. The mean follow-up was 26.45 ± 21.71 months for ADA patients and 56.60 ± 56.04 months for IFX patients. The overall decrease of uveitis frequency during the first 12 months of treatment was 66.7% in the IFX group and 84.2% in the ADA group, compared to the previous 12 months (p = 0.09). A significantly higher corticosteroid dosage was found among patients treated with ADA at the last follow-up visit (p = 0.008). The percentage of patients co-administered with corticosteroids was significantly higher among ADA patients both at the 12-month visit (p = 0.03) and at the last visit (p = 0.0004). The frequency of uveitic macular edema (UME) was significantly higher among patients treated with ADA compared to those treated with IFX at the 12-month assessment (p = 0.015) and at the last follow-up visit (p = 0.011); central macular thickness was significantly higher in ADA group compared to the IFX group at the last follow-up assessment (p = 0.04). ADA and IFX have shown a similar efficacy in controlling uveitis relapses, but IFX showed a more pronounced corticosteroid sparing effect and a significantly higher capacity in resolving UME compared to ADA.

AB - To compare the efficacy of adalimumab (ADA) and infliximab (IFX) in patients with non-infectious intermediate uveitis, posterior uveitis, and panuveitis. Demographic, clinical, instrumental, and therapeutic data from patients enrolled were collected at the start of treatment, at 12-month follow-up, and at the last follow-up assessment. One hundred seven patients (46 females, 187 eyes) were enrolled, 66 (61.7%) treated with ADA and 41 (38.3%) with IFX. Bilateral involvement was observed in 80 cases. The mean follow-up was 26.45 ± 21.71 months for ADA patients and 56.60 ± 56.04 months for IFX patients. The overall decrease of uveitis frequency during the first 12 months of treatment was 66.7% in the IFX group and 84.2% in the ADA group, compared to the previous 12 months (p = 0.09). A significantly higher corticosteroid dosage was found among patients treated with ADA at the last follow-up visit (p = 0.008). The percentage of patients co-administered with corticosteroids was significantly higher among ADA patients both at the 12-month visit (p = 0.03) and at the last visit (p = 0.0004). The frequency of uveitic macular edema (UME) was significantly higher among patients treated with ADA compared to those treated with IFX at the 12-month assessment (p = 0.015) and at the last follow-up visit (p = 0.011); central macular thickness was significantly higher in ADA group compared to the IFX group at the last follow-up assessment (p = 0.04). ADA and IFX have shown a similar efficacy in controlling uveitis relapses, but IFX showed a more pronounced corticosteroid sparing effect and a significantly higher capacity in resolving UME compared to ADA.

KW - Behçet’s disease

KW - Macular edema

KW - Retinal vasculitis

KW - TNF-blocking antibodies

KW - Uveitis

UR - http://www.scopus.com/inward/record.url?scp=85051545122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051545122&partnerID=8YFLogxK

U2 - 10.1007/s10067-018-4228-6

DO - 10.1007/s10067-018-4228-6

M3 - Article

AN - SCOPUS:85051545122

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

ER -